Related Experiment Video

Updated: Aug 10, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level

D B Ludlum1

  • 1Department of Pharmacology and Molecular Toxicology, University of Massachusetts Medical School, Worcester 01655-0126, USA.

Cancer Investigation
|January 1, 1997
PubMed

Insights

Chloroethylnitrosoureas fight cancer by crosslinking DNA, but resistance can develop. Inhibiting DNA repair enzymes like O6-alkylguanine-DNA alkyltransferase may restore drug sensitivity.

Area of Science:

  • * Pharmacology
  • * Molecular Biology
  • * Organic Chemistry

Background:

  • * Chloroethylnitrosoureas (CENUs) are a class of anticancer agents.
  • * Their development stemmed from observing the efficacy of N-methyl-N'-nitro-N-nitrosoguanidine against L1210 cells.
  • * CENUs exert antitumor activity through DNA crosslinking, primarily forming cytosine-guanine crosslinks.

Purpose of the Study:

  • * To investigate the mechanism of action and resistance of chloroethylnitrosoureas.
  • * To explore strategies for overcoming drug resistance in cancer therapy.
  • * To identify novel agents with improved DNA-targeting specificity and enhanced efficacy.

Main Methods:

  • * Chemical synthesis of chloroethylnitrosoureas.
  • * Studies on DNA interaction and crosslinking assays.
  • * Investigation of enzyme kinetics and inhibition of DNA repair pathways.

Main Results:

  • * Chloroethylnitrosoureas function by forming DNA crosslinks, a key step in their cytotoxic effect.
  • * Resistance to CENUs is often mediated by the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase.
  • * Inhibition of O6-alkylguanine-DNA alkyltransferase can restore sensitivity to CENUs in resistant cells.

Conclusions:

  • * Understanding DNA repair mechanisms is crucial for overcoming chloroethylnitrosourea resistance.
  • * Developing specific DNA-damaging agents and potent repair enzyme inhibitors holds promise for improved cancer treatment.
  • * Further research is needed to elucidate additional resistance mechanisms and develop novel therapeutic strategies.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...